Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01772472
Title A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Hoffmann-La Roche
Indications

Her2-receptor positive breast cancer

Therapies

Ado-trastuzumab emtansine

Trastuzumab

Age Groups: adult
Covered Countries USA | CAN


No variant requirements are available.